Wall Street analysts forecast that Exelixis, Inc. (NASDAQ:EXEL) will announce $195.01 million in sales for the current quarter, according to Zacks. Five analysts have made estimates for Exelixis’ earnings. The highest sales estimate is $220.09 million and the lowest is $172.30 million. Exelixis posted sales of $120.07 million during the same quarter last year, which suggests a positive year-over-year growth rate of 62.4%. The business is scheduled to issue its next quarterly earnings report on Monday, February 25th.

On average, analysts expect that Exelixis will report full-year sales of $819.79 million for the current fiscal year, with estimates ranging from $796.20 million to $845.31 million. For the next financial year, analysts anticipate that the company will report sales of $928.46 million, with estimates ranging from $849.80 million to $1.00 billion. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for Exelixis.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Thursday, November 1st. The biotechnology company reported $0.41 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.19 by $0.22. Exelixis had a net margin of 49.53% and a return on equity of 55.71%. The firm had revenue of $225.40 million for the quarter, compared to analyst estimates of $174.14 million. During the same quarter last year, the firm posted $0.26 earnings per share. Exelixis’s revenue for the quarter was up 47.8% compared to the same quarter last year.

A number of analysts have recently issued reports on EXEL shares. Guggenheim started coverage on shares of Exelixis in a research note on Monday, September 17th. They set a “buy” rating on the stock. Goldman Sachs Group started coverage on shares of Exelixis in a research note on Monday, September 17th. They set a “neutral” rating and a $22.00 price objective on the stock. Morgan Stanley started coverage on shares of Exelixis in a research note on Monday, September 10th. They set an “underweight” rating and a $19.00 price objective on the stock. BidaskClub upgraded shares of Exelixis from a “strong sell” rating to a “sell” rating in a research note on Thursday, August 30th. Finally, Oppenheimer set a $40.00 price objective on shares of Exelixis and gave the company a “buy” rating in a research note on Thursday, November 1st. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $29.44.

In other news, Director George A. Scangos sold 40,000 shares of the firm’s stock in a transaction that occurred on Monday, December 3rd. The shares were sold at an average price of $21.16, for a total transaction of $846,400.00. Following the completion of the sale, the director now owns 1,505,481 shares of the company’s stock, valued at $31,855,977.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Patrick J. Haley sold 20,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 7th. The stock was sold at an average price of $17.32, for a total transaction of $346,400.00. The disclosure for this sale can be found here. Insiders have sold 289,367 shares of company stock worth $5,219,346 in the last quarter. Insiders own 4.80% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. Marshall Wace LLP grew its position in shares of Exelixis by 109.1% during the third quarter. Marshall Wace LLP now owns 1,627,313 shares of the biotechnology company’s stock worth $28,836,000 after buying an additional 849,096 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Exelixis by 3.2% during the third quarter. Vanguard Group Inc. now owns 26,527,089 shares of the biotechnology company’s stock worth $470,060,000 after buying an additional 834,478 shares in the last quarter. Legal & General Group Plc grew its position in shares of Exelixis by 5.5% during the third quarter. Legal & General Group Plc now owns 326,613 shares of the biotechnology company’s stock worth $5,788,000 after buying an additional 16,918 shares in the last quarter. Rehmann Capital Advisory Group grew its position in shares of Exelixis by 1,417.1% during the third quarter. Rehmann Capital Advisory Group now owns 8,966 shares of the biotechnology company’s stock worth $506,000 after buying an additional 8,375 shares in the last quarter. Finally, New Mexico Educational Retirement Board acquired a new stake in shares of Exelixis during the third quarter worth approximately $1,175,000. 77.24% of the stock is owned by institutional investors and hedge funds.

Shares of EXEL traded down $0.56 during mid-day trading on Friday, reaching $20.54. 3,603,426 shares of the stock traded hands, compared to its average volume of 3,775,444. The firm has a market capitalization of $6.15 billion, a P/E ratio of 40.27, a P/E/G ratio of 1.22 and a beta of 2.34. Exelixis has a 12-month low of $13.42 and a 12-month high of $32.20. The company has a quick ratio of 8.54, a current ratio of 8.66 and a debt-to-equity ratio of 0.01.

About Exelixis

Exelixis, Inc, a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Featured Story: Can individual investors take part in an IPO?

Get a free copy of the Zacks research report on Exelixis (EXEL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.